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Parkinson’s disease (PD) is a common progressive neurodegenerative disorder. The major pathological hallmarks of PD are the
selective loss of nigrostriatal dopaminergic neurons and the presence of intraneuronal aggregates termed Lewy bodies (LBs), but
the pathophysiological mechanisms are not fully understood. Epidemiologically, environmental neurotoxins such as pesticides
are promising candidates for causative factors of PD. Oxidative stress and mitochondrial dysfunction induced by these toxins
could contribute to the progression of PD. While most cases of PD are sporadic, speciﬁc mutations in genes that cause familial
forms of PD have led to provide new insights into its pathogenesis. This paper focuses on animal models of both toxin-induced
and genetically determined PD that have provided signiﬁcant insight for understanding this disease. We also discuss the validity,
beneﬁts, and limitations of representative models.
1.Introduction
Parkinson’s disease (PD) is one of the most common
chronic neurodegenerative disorders. It is characterized by a
variety of motor (bradykinesia, rigidity, tremor, and postural
instability)andnonmotor(autonomicdisturbancesandpsy-
chosis) symptoms. Although it can be diagnosed accurately,
no therapeutic strategies can cure or completely block the
progression of PD. Pathologically, PD is characterized by
the severe loss of dopaminergic (DAergic) neurons in the
pars-compacta nigra and the presence of proteinaceous α-
synuclein inclusions, called Lewy bodies (LBs), which are
present in neurons of the central nervous system (speciﬁc
cortical regions, brain stem, and spinal cord), peripheral
autonomic nervous system, enteric nervous system (ENS),
andcutaneousnerves[1–3].Similartootherneurodegenera-
tivediseases,suchasAlzheimer’sdisease,ageisthemajorrisk
factorforPDalthough10%ofthepeoplewiththediseaseare
younger than 45.
Although PD is regarded as a sporadic disorder, remark-
ably few environmental causes or triggers have been iden-
tiﬁed [4–6]. Pesticides and herbicides are the most likely
candidates for environmental agents associated with the
pathogenesis of PD. On the other hand, PD characteristics
are seen in a number of familial motor disorders caused
by diﬀerent genetic factors. Animal models of neurode-
generative diseases, including PD, have in general been
quiteinstructiveinunderstandingtheirpathogenesis.Ideally,
animal models of PD, whether induced by environmental
risk factors (neurotoxins) or genetic manipulations, should
faithfully reproduce the clinical manifestations (behavioral
abnormalities), pathological features, and molecular dys-
functions characterizing the disease. Unfortunately, animal
modelsrarelymimictheetiology,progression,andpathology
of PD completely, and in most cases, only partial insight
can be gained from these studies. Despite these diﬃculties,
animal models are considered to be very helpful in the
development of therapies to treat PD. In this paper, we
discuss recently developed neurotoxin-induced and genetic
m o d e la n i m a l so fP D .
2. AnimalModelsofPDInducedbyNeurotoxins
PD is currently viewed as a multifactorial disease. Environ-
mental exposures, particularly to pesticides, are thought to
be involved in the pathogenesis of sporadic PD. Speciﬁcally,
the herbicide Paraquat (PQ) and the fungicide Maneb
(MB; manganese ethylene-bis-dithiocarbamate) have been
associated with the incidence of PD [7, 8] .H o w e v e r ,ac a u s a l2 Parkinson’s Disease
role for pesticides in the etiology of PD has yet to be
deﬁnitively established. In animal models, PD-like disorders
induced by neurotoxins or other chemical compounds have
led to a better understanding of the pathophysiology of PD
(Table 1).
3. 1-Methyl-4-Phenyl-1,2,3,6-
Tetrahydropyridine(MPTP)
In 1979 and 1983, MPTP was initially identiﬁed as a
strong neurotoxin when heroin addicts accidentally self-
administered MPTP and developed an acute form of
parkinsonism that was indistinguishable from idiopathic
PD [9, 10]. A detailed neuropathological study of MPTP-
induced parkinsonism in humans showed severe neuronal
degeneration in the substantia nigra and the absence of LBs
[11]. The lack of LBs may have reﬂected the age of the
patient and the duration of exposure to MPTP. The tragic
results of MPTP poisoning in the heroin addicts led to
the development of MPTP-induced rodent and nonhuman
primate animal models of PD, which have proved extremely
valuable [12–16]. The MPTP-exposed primates show good
response to therapy with L-3,4-dihydroxy-L-phenylalanine
(L-DOPA) and dopamine (DA) receptor agonists [15, 16].
However, rats are relatively insensitive to MPTP neurotox-
icity compared with primates. Rats given MPTP at doses
comparable to those used in mice do not show remarkable
neurodegeneration [17, 18]. Only high doses of MPTP cause
DAergic neurodegeneration in rats, indicating that complete
blockade of the DA receptors is required for them to display
signs of parkinsonism. Mice, like rats, are also less sensitive
to MPTP than primates [19, 20].
This model also shows pathological changes in the ENS,
as observed in PD. In PD, gastrointestinal (GI) dysfunction
was hypothesized to depend on neuronal degeneration in the
ENS that is similar to that seen in the CNS. Recent studies
show that the administration of MPTP results in decreased
tyrosinehydroxylase-(TH-)positiveentericneuronsinmice,
indicating that the MPTP model mice should be suitable
for understanding the extranigral pathophysiology of PD
[21, 22].
4.6-Hydroxy-Dopamine(6-OHDA)
Like MPTP, 6-OHDA is a neurotoxin that has been suc-
cessfully used in induction animal models of PD. 6-OHDA’s
strong neurotoxic eﬀects were described by Ungerstedt in
1971, in a study presenting the ﬁrst example of using a
chemical agent to produce an animal model of PD [23].
Since 6-OHDA cannot cross the blood-brain barrier (BBB),
systemic administration fails to induce parkinsonism. This
induction model requires 6-OHDA to be injected into the
substantia nigra, medial forebrain bundle, and striatum [24,
25]. The eﬀects resemble those in the acute MPTP model,
causing neuronal death over a brief time course (12 hours to
2-3 days).
Interestingly, the intrastriatal injection of 6-OHDA
causes progressive retrograde neuronal degeneration in the
substantia nigra and ventral tegmental complex (ST-VTA)
[25–27]. As in PD, DAergic neurons are killed, and the
non-DAergic neurons are preserved. However LBs do not
form. Typically, 6-OHDA is used as a hemiparkinson model,
in which its unilateral injection into the substantia nigra
causes asymmetric motor behavior (turning, rotation) when
apomorphine, a DAergic receptor agonist, or amphetamine,
a dopamine releasing agent, is given systemically. In this
model, the quantiﬁable motor behavior is a major advantage
for screening pharmacological screening agents for their
eﬀectsontheDAergicsystemandfortestingcellreplacement
therapies [28–30].
5. Rotenone
Rotenone is a naturally occurring complex ketone pesticide
derived from the roots of Lonchocarpus species. It can rapidly
cross cellular membranes without the aid of transporters,
including the BBB. Rotenone is a strong inhibitor of complex
I, which is located at the inner mitochondrial membrane and
protrudes into the matrix.
In 2000, Betarbet et al. demonstrated in rats that
chronic systemic exposure to rotenone causes many features
of PD, including nigrostriatal DAergic degeneration [31].
Importantly, pathological features match those seen in
typical PD. For example, many of the degenerating neurons
have intracellular inclusions that are morphologically similar
to LBs. These inclusions also show immunoreactivity for
α-synuclein and ubiquitin, like true LBs [31, 32]. The
rotenone-administered model animals also reproduce all
the behavioral and pathological features seen in the typical
form of human PD. However, rotenone-injected rats without
nigrostriatal DAergic neuronal loss demonstrate the same
abnormal motor behaviors as those with such pathological
features [32, 33]. This ﬁnding suggested that the abnormal
behaviors of PD could depend, at least partly, on the
damage to non-DAergic neurons in the nigrostriatal area.
Furthermore, rotenone exposure also causes the loss of
myenteric neurons in the rat [34].
6.ParaquatandManeb
Because of its close structural similarity to 1-methyl-
4-phenylpyridinium (MPP+, the active metabolite form
of MPTP), an herbicide, 1,1 -dimethyl-4,4 -bipyridinium,
named paraquat has been suggested as a risk factor for PD
[35]. The systemic administration of paraquat to adult mice
results in a signiﬁcant decrease in substantia nigra DAergic
neurons, a decline in striatal dopamine nerve terminal
density, and a neurobehavioral syndrome characterized by
reduced ambulatory activity [36]. These data support the
ideathatparaquatcrossestheBBBtocausedestructionofthe
dopamine neurons in the substantia nigra, like MPP+ [36].
The prolonged exposure to paraquat leads to a remarkable
accumulation of α-synuclein-like aggregates in neurons of
the substantia nigra pars compacta in mice [37]. Chronic
exposure to paraquat also reduces the expression of the
nicotinic acetylcholine receptor (nAChR) subunit α3/α6β2∗Parkinson’s Disease 3
Table 1: Representative neurotoxin-induced mammalian models of Parkinson’s disease.
Neurotoxin Behavioral and pathological features Molecular mechanisms
MPTP
(1) Parkinsonism (akinesia, rigidity, and tremor) with
acute onset
(2) Relatively less potent in rodents
(3) Good response to L-DOPA and DA-agonists
(4) Loss of TH-neurons (-ﬁbers) and DA-content in
nigrostriatal region
(5) Loss of TH-neurons (-ﬁbers) in ENS
(6) α-Synuclein-positive inclusions
(7) No typical LBs
( 1 )E a s i l yc r o s s e st h eB B B
(2) Converted to MPP+ in glial cells
(3) Transferred into mitochondria by transporters
(4) Inhibits electron transport chain complex I
(5) Upregulation of iNOS, NADPH-oxidase, and ROS
(6) Microglial activation
6-OHDA
(1) Intracerebral administration
(2) Quantiﬁable locomotor abnormalities (rotation,
akinsesia)
(3) Good response to L-DOPA and DA-agonists
(4) Loss of TH-neurons (-ﬁbers) and DA-content in
nigrostriatal region
(5) No typical LBs
(1) Transferred into mitochondria by transporters
(2) Inhibits electron transport chain complex I
(3) Microglial activation
Rotenone
(1) Parkinsonism (bradykinesia, ﬁxed posture, and
rigidity)
(2) Good response to L-DOPA and DA-agonists
(3) Loss of TH-neurons (-ﬁbers) and DA-content in
nigrostriatal region
(4) α-Synuclein-positive inclusions, resemblance to
true LBs
(5) Loss of myenteric neurons
( 1 )E a s i l yc r o s s e st h eB B B
(2) Inhibits electron transport chain complex I
(3) Upregulation of NADPH-oxidase
(4) Microglial activation
Paraquat (+ Maneb)
(1) Parkinsonism similar to that of induced by MPTP
(2) Loss of DA-content in nigrostriatal region
(3) α-Synuclein-positive inclusions with long exposure
(1) Crosses the BBB by neutral amino acid transporter
(2) Inhibits electron transport chain complex I
(3) Reduction of nAchR-mediated DA release
(4) Inhibits complex III (Maneb)
MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA: 6-hydroxy-dopamine; L-DOPA: L-3,4-dihydroxy-L-phenylalanine; TH: tyrosine hydroxy-
lase; DA: dopamine; ENS: enteric nervous system; LB: Lewy body; BBB: blood-brain barrier; MPP+: 1-methyl-4-phenylpyridinium; iNOS: inducible nitric
oxide synthase; ROS: reactive oxygen species; nAchR: nicotinic acetylcholine receptor.
(the asterisk indicates the possible presence of additional
subunits). Normally, the activation of both nAChR subtypes
stimulates DA release in the striatum [38–40]. The injection
of paraquat selectively reduces the α3/α6β2∗-mediated DA
release from the striatum in primates [41].
Manganese ethylenebis-dithiocarbamate (Maneb) is an
organomanganese fungicide that is broadly used in agricul-
ture and is a putative causative agent for PD. Surprisingly,
Thiruchelvam et al. found that the neurotoxic eﬀects of
maneb or paraquat on the nigrostriatal DA system in mice
are synergistically potentiated in combination [42]. Their
report argued that this ﬁnding has important implications
for the human risk of PD, because the marked geographical
overlap in the estimated annual agricultural applications of
paraquat and maneb means that people living in these areas
may be exposed to the synergistic neurotoxicity of these two
agents [42, 43].
7. Pathophysiological Mechanismsof
DAergic Neurotoxins
All the representative neurotoxin-induced PD models
described above show defective mitochondrial function,
manifested by the inhibition of mitochondrial complex I
or III. MPTP is a highly lipophilic agent. After its systemic
administration, MPTP rapidly crosses the BBB. Once in
the brain, MPTP is converted to 1-methyl-4-phenyl-2,3-
dihydropyridium (MPDP+) in glial cells (astrocytes) and
serotonin neurons by monoamine oxidase B (MAO-B) and
then spontaneously oxidizes to MPP+ [44, 45]. Thereafter,
MPP+ is released into the extracellular space. Unlike MPTP,
MPP+ is a polar molecule that cannot freely enter DAergic
neurons. Thus, a plasma membrane transport system is
required. MPP+ has a high aﬃnity for dopamine trans-
porter (DAT) as well as for norepinephrine and serotonin
transporters [46, 47]. Once inside DAergic neurons, MPP+
can accumulate in mitochondria and impair mitochondrial
respiration by inhibiting complex I in the electron transport
chain [44, 48], which induces the generation of reactive
oxygen species (ROS). MPP+ can also bind to vesicu-
lar monoamine transporters (VMATs), which help move
selected materials into synaptic vesicles containing DA [49].
MPP+ can also remain in the cytoplasm and interact with
cytosolic enzymes [50].
Inducible nitric oxide synthase (iNOS) is also involved
in the pathogenesis of MPP+-induced parkinsonism in
animal models. Increased iNOS has also been found in
the substantia nigra of autopsied PD patients, indicating
that NO overproduction is a feature of the human disease4 Parkinson’s Disease
[51, 52]. Excess NO could contribute to the formation
of free radicals, which could damage DAergic neurons,
leading to the development of PD symptoms. Mice null
for iNOS show a resistance to neuronal damage by MPTP,
and iNOS inhibitors protect against the degeneration of
DAergic neurons in MPTP-treated mice [53, 54]. Further-
more, microglial cells can be activated by the formation
of free radicals and iNOS-mediated damage, and thereby
exacerbate the toxicity of MPTP [55–57]. Finally, MPTP
can also upregulate NADPH-oxidase in the substantia nigra
of mice [56], which is signiﬁcant because NADPH-oxidase
appears to be ubiquitously expressed in all brain regions
and metabolizes molecular oxygen, generating superoxide
as a product. In fact, MPTP toxicity is diminished in mice
lacking functional NADPH-oxidase, indicating a pivotal role
for superoxide ions in the neurotoxicity induced by MPTP
[56].
The toxicity of 6-OHDA also involves mechanisms of
oxidative stress. 6-OHDA can be taken up by DAergic
neurons through DAT [58, 59]. Once transported into neu-
rons, 6-OHDA is oxidized like DA. The oxidized molecule
generates free radicals inhibits mitochondrial complex I and
produces superoxide and hydroxyl radicals [58, 59]. It is
not only toxic to the DAergic neurons but can also induce
microglial activation [59].
Like MPTP, the pesticide rotenone is very lipophilic,
crosses the BBB, and is distributed evenly throughout the
brain [59, 60]. It can enter mitochondria, where it inhibits
complex I of the electron transport chain with high aﬃnity
[59]. Interestingly, the inhibition of microglial activation by
anantibiotic,minocycline,canattenuatetheneurotoxicity of
rotenone [61]. Gao et al. also showed that the neurotoxicity
of rotenone is reduced in neuron-glia cocultures from
NADPH oxidase-null mice [62]. The DA uptake of the
neuron-enriched cultures was not aﬀected by the addition of
microglia from NADPH oxidase-null mice, the addition of
microglia from wild-type (WT) mice signiﬁcantly increased
the sensitivity of DAergic neurons either from WT or
knockout (KO) mice to rotenone neurotoxicity. These data
indicate that microglial NADPH oxidase, but not neuronal
NADPH oxidase, is responsible for the NADPH oxidase-
mediated neurotoxicity of rotenone [62]. Paraquat mainly
crosses the BBB through the neutral amino acid transporter
[63–65]. Once in the brain, it is selectively taken up by
the terminals of DA-containing neurons in the substantia
nigra by the DAT, and it inhibits mitochondrial complex I
[63]. Maneb contains a major active fungicidal component,
manganese ethylene-bis-dithiocarbamate (Mn–EBDC). In
a rat model in which Mn–EBDC is directly delivered to
the lateral ventricles, Mn–EBDC causes selective DAergic
neurodegeneration [66]. Mn–EBDC preferentially inhibits
mitochondrial complex III [66].
8.GeneticAnimalModelsofPD
Although the etiopathogenesis (including environmental
factors) of PD is not fully understood, the extensive exam-
ination of human postmortem material, the genetic analysis
of patients, and the study of experimental animal models
have shed signiﬁcant light on the molecular mechanisms
involved in its progression. However, since the number of
patients with familial PD is extremely low compared to the
number with sporadic PD, genetic studies in aﬀected human
families are very diﬃcult. Therefore, the development of
animal genetic models for PD is especially important, and
such models provide an opportunity not only to investigate
the genetic etiology of PD but also to identify new factors
that could be invaluable in terms of diagnosis, drug design,
and/ortherapy[67,68].Eveninvertebrateanimals,forexam-
ple, Drosophila melanogaster, are useful models for surveys
of human PD. While their numbers of neurons and glia
are obviously much smaller than in rodents and primates,
Drosophila have the same types of neuron-glia systems, and a
great number of genes and molecular transduction pathways
are conserved between Drosophila and humans.
In recent years, several genetic animal models of PD have
been reported, including models for autosomal-dominant
(AD) inheritance patterns. The genes manipulated in these
models include α-synuclein, leucine rich repeat kinase 2
(LRRK2), ubiquitin carboxyl-terminal esterase L1 (UCHL1),
and high temperature requirement A2 (HTRA2/Omi)
(Table 2). There are also models of autosomal-recessive (AR)
inherited PD, which involve KO or knockdown genes for
parkin, DJ-1,a n dphosphatase and tensinhomolog- (PTEN-)
induced novel kinase 1 (PINK1)( Table 3). In addition, we
will review a PD mouse model deﬁcient in nuclear receptor-
related 1 (Nurr1), also named nuclear receptor subfamily 4,
group A, member 2 (NR4A2), which is a susceptibility gene
for familial PD (Table 2).
8.1. α-Synuclein. α-synuclein was the ﬁrst gene linked to
an AD-type familial PD, called Park1. The identiﬁcation
of an α-synuclein mutation in this family revolutionized
PD research, since α-synuclein is the main component of
LBs, which are observed in the sporadic PD brain. This
striking result strongly indicates that genetic and sporadic
PD may share similar etiologies and that investigating
α-synuclein-mediated pathogenesis in familial PD could
uncover important information about sporadic PD. Three
missense mutations of α-synuclein, encoding the substitu-
tions A30P, A53T, and E46K, have been identiﬁed in familial
PD [67–70]. Furthermore, the duplication or triplication
of α-synuclein is suﬃcient to cause PD, suggesting that the
level of α-synuclein expression is a critical determinant of
PD progression [71, 72]. Even though no direct relationship
between sporadic PD and α-synuclein expression has yet
been shown, the existence of several polymorphisms in the
promoter or 3 -UTR of the α-synuclein gene suggests that its
expression level might be a risk factor [73–75].
Human α-synuclein is an abundant 140-amino acid
presynaptic phosphoprotein involved in vesicle handling
and neurotransmitter release. Mutations in α-synuclein that
increase the propensity for misfolding are probably deleteri-
ous, because the misfolded forms are toxic, and they induce
cell death in vitro [76, 77]. Among the variety of abnormal
forms that mutant α-synuclein can adopt, protoﬁbrils and
ﬁbrils seem to be the most toxic [77]. These demonstrationsParkinson’s Disease 5
Table 2: Autosomal-dominant PD models.
Gene Animal Manipulation DA neuron loss LB-like inclusions1 DA-responsive motor deﬁcits2 References
a-synuclein
(PARK1)
Nematode Transgenic Yes§ No Yes [79, 80]
Fly Transgenic Yes Yes Yes [78]
Mouse Transgenic No Yes§ (PrP promoter) Yes§ (PDGFβ promoter) [81–91]
Rat Transgenic Yes No Yes [92–95]
Monkey Transgenic Yes No ND [96]
UCHL1
(PARK5)
Mouse Transgenic Yes No Yes [105, 106]
LRRK2
(PARK8)
Nematode Transgenic Yes ND ND [116]
Fly Transgenic Yes No Yes [113–115]
Mouse Transgenic No No Yes [117–119]
DA, dopamine; LB, Lewy body; ND, not determined; PrP, prion; PDGFβ platelet-derived growth factor β.
1LB-like inclusions by deﬁnition contain ﬁlamentous α-synuclein.
2ND could include some degree of behavioral impairment in spontaneous and locomotor activity and in response to sensory stimulation.
§Controversial. The opposite result has also been shown.
Table 3: Autosomal-recessive PD models and other causative genes of PD.
Gene Animal Manipulation DA neuron loss LB-like inclusion1 DA-responsive motor deﬁcits2 References
Parkin (PARK2)
Nematode Knockout No No No [124]
Fly Knockout Yes No Yes [125, 126]
Transgenic Yes No Yes [131, 132]
Mouse Knockout No No ND [127–130]
Transgenic Yes Yes ND [133]
PINK1 (PARK6) Fly Knockout Yes No Yes [135, 136]
Mouse Knockout No No ND [137–139]
DJ-1 (PARK7) Fly Knockout Yes No Yes [144–148]
Mouse Knockout No No ND [149–151]
HtrA2/Omi (PARK13) Fly Knockout No No No [153]
Mouse Knockout No No ND [154, 155]
Nurr1 (NR4A2)M o u s e K n o c k o u t Y e s N o N D [ 158–160]
DA, dopamine; LB, Lewy body; ND, not determined.
1LB-like inclusions by deﬁnition contain ﬁlamentous α-synuclein.
2ND could include some degree of behavioral impairment in spontaneous and locomotor activity and in response to sensory stimulation.
of α-synuclein toxicity in vitro led to the creation and
extensive analysis of many α-synuclein-based animal models
of PD.
Although ﬂies (Drosophila) and nematodes (C. ele-
gans) do not have complex nervous systems compared to
vertebrates and do not express endogenous α-synuclein,
they are useful for identifying genetic and pharmacological
modiﬁers of α-synuclein and its product. In Drosophila, the
overexpression of WT and mutated (A30P, A53T) human
α-synuclein causes the age-dependent loss of dorsomedial
DAergic neurons, an accumulation of LB-like ﬁlamentous
inclusions with α-synuclein immunoreactivity, and com-
promised locomotor activity (climbing ability) [78]. In
C. elegans, α-synuclein overexpression leads to accelerated
DAergic neuronal loss and motor impairment [79, 80].
However, the neurons of these nematodes do not contain
notable synuclein-containing inclusions.
Many diﬀerent mouse lines that overexpress α-synuclein
under various promoters have been generated in the last ten
years, and most have been described in recent reviews [81–
83]. Mice expressing α-synuclein containing two mutations
(A30P + A53T) under the TH promoter show progressive
declinesinlocomotoractivityandthelossofsubstantianigra
neurons and striatal DA content [84, 85]. Similarly, mice
overexpressing WT human α-synuclein under the neuron-
speciﬁc platelet-derived growth factor β (PDGFβ)p r o m o t e r
show reduced TH immunoreactivity and DA content in the
striatum and impaired motor performance [86]. Mice over-
expressing WT human α-synuclein under another neuron-
speciﬁc promotor, Thy1, show strong widespread expression
in cortical and subcortical neurons, including the substantia
nigra pars compacta, but no glial, spinal, or neuromus-
cular pathology [87–89]. These mice have an increased
sensitivity to mitochondrial damage from low doses of
MPTP [89]. Mice in which the mouse prion promoter
(mPrP) is used to drive the expression of α-synuclein A53T
show α-synuclein aggregation, ﬁbrils and truncation, α-
synuclein phosphorylation, ubiquitination, and progressive6 Parkinson’s Disease
age-dependent neurodegeneration, just as in humans [90,
91].
Several viral vectors, primarily lentiviruses and adeno-
associatedviruses(AAVs),havebeenusedtodriveexogenous
α-synuclein. Because viral vector delivery requires stereo-
tactic injections within or near the site of the neuronal
cell bodies in the substantia nigra pars compacta, rats are
generally used for these studies although the model has been
reproduced in other rodents [92–95]. The overexpression of
human WT or A53T mutant α-synuclein by AAVs in the SNc
neurons of rats causes the progressive age-dependent loss of
DA neurons, motor impairment, and α-synuclein-positive
cytoplasmic inclusions [92]. Kirik et al. also overexpressed
WT or A53T mutant α-synuclein in marmosets [96], in
which the α-synuclein protein was expressed in 90%–95%
of all substantia nigra DA neurons. The transduced neurons
showed evidence of severe pathology, including α-synuclein-
positive cytoplasmic inclusions, granular deposits, and loss
of the TH-positivity.
It is particularly notable that the phenotypic outcome of
α-synuclein overexpression in mice heavily depends on the
promoter used to drive transgene expression. Unfortunately,
mostofthesemodelsfailtoaccuratelymimicPDinthatthere
is no progressive loss of DA neurons. The loss of TH-positive
cell bodies in the substantia nigra does not necessarily
indicate cell death. Despite the lack of overt degenerative
pathology in the DA-positive neurons, obvious locomoter
abnormalities due to degeneration of the nigrostriatal system
and a lack of DA responsiveness are observed in the various
mouse α-synuclein models. Thus, most of these lines are
excellent models of α-synuclein-induced neurodegenerative
disorders, such as PD.
Although mutated α-synuclein causes human familial
PD, α-synuclein’s physiological roles in PD are not fully
understood. In KO mice of α-synuclein, neuronal develop-
ment and the formation of presynaptic terminals are normal
[97] .M o r e o v e r ,d o u b l eK Om i c et h a tl a c kα-a n dβ-synuclein
exhibit normal basic brain functions and survive to adult-
hood [98]. Thus, the loss of α-synuclein function is unlikely
to play a role in the pathogenesis of α-synuclein-induced
neurodegeneration. Meanwhile, α-synuclein KO mice show
reduced rearing activity in the open ﬁeld, decreased DA
content in the striatum, and a decrease in the reserve
pool of vesicles in the hippocampus [97, 99]. These results
indicate that α-synuclein may play a regulatory role in vivo,
possiblyintheﬁnetuningofsynapticplasticityand/orvesicle
maintenance. Interestingly, several lines of α-synuclein-null
mice have a complete or partial resistance to the MPTP [100,
101]. Dauer et al. showed that this resistance is not due to
abnormalities of the DA transporter, which appears to func-
tion normally in α-synuclein null mice [100]. These reports
indicatethatα-synucleinisnotobligatorilycoupledtoMPTP
sensitivity, but can inﬂuence MPTP toxicity on some genetic
background.
8.2. UCHL1. A rare AD-inherited form of PD, PARK5, is
caused by a missense mutation in the UCHL1 gene. UCHL1
constitutes 1%-2% of the brain proteins and functions
in the ubiquitin-proteasome system. The ubiquitin hydro-
lase activity of UCHL1 is important for freeing reusable
ubiquitin monomers. The missense mutation in PARK5
causes an Ile93Met substitution in the UCHL1 protein
(UCHL1Ile93Met), and this mutant was initially shown to
have decreased ubiquitin hydrolase activity [102]. Interest-
ingly, UCHL1 is detected in LBs in sporadic PD cases [103].
These ﬁndings initiated a debate on whether the Ile93Met
mutation causes a gain of function (toxicity) or loss of
function (deﬁciency).
The gracile axonal dystrophy (gad) mouse is an AR-
mutant that shows sensory ataxia at an early stage, followed
by motor ataxia. Saigoh et al. showed that these mice exhibit
spontaneous intragenic deletion of the UCHL1 gene and do
not express the UCHL1 protein [104] .T h e s em i c ed on o t
show obvious pathological changes in the nigrostriatal DA
pathway;inparticular,thereisnolossofDAcellbodiesinthe
substantia nigra. Setsuie et al. generated UCHL1Ile93Met-
o v e r e x p r e s s i n gm i c ea n dr e p o rt e dar e d u c t i o ni nt h eD A e r g i c
neurons of the substantia nigra and of the DA content
in the striatum [105]. These mice show behavioral and
pathological phenotypes of parkinsonism at 20 weeks of
age. Moreover, recently, Yasuda et al. performed a viral
vector-mediated α-synuclein injection into the substantia
nigra of the UCHL1Ile93Met transgenic mice [106]. These
mice show a signiﬁcantly enhanced loss of DA-positive
cell bodies in the substantia nigra and of DA content in
the striatum. The neurotoxicity is enhanced by PARK5-
associated UCHL1Ile93Met mutant, but not inﬂuenced by
the loss of UCH-L1 WT protein in vivo, indicating that the
UCHL1Ile93Met toxicity results from a gain of function.
8.3. LRRK2. The LRRK2 mutation is another type of AD-
PD, called PARK8. LRRK2 is a large protein containing
a serine/threonine kinase and a GTPase domain that is
localized to membranous structures [107]. The frequency
of the common LRRK2 Gly2019Ser mutation was 1% in
patients with sporadic PD and, interestingly, 4% of patients
with hereditary PD [108]. The risk of PD when the LRRK2
Gly2019Ser mutation was present was 28% at age 59 years,
51% at 69 years, and 74% at 79 years. The motor symptoms
and non-motor symptoms of LRRK2-associated PD are
morebenignthanthoseofidiopathicPD.Inautopsiedtissue,
the LB pathology was present in a representative LRRK2
G2019S case, indicating that LRRK2 and α-synuclein share
some pathogenic mechanisms [109]. Yet, LRRK2 may play
a role in neuronal outgrowth and guidance, and its precise
physiological function remains to be clariﬁed [110].
dLRRK is a Drosophila orthologue of LRRK2, and it
shows elevated expression in DA neurons of the head [111,
112]. Liu et al. overexpressed constructs with mutations
similar to those found in patients (G2019S), in Drosophila
[113].TheneuronalexpressionofLRRK2orLRRK2-G2019S
produces an adult-onset selective loss of DAergic neurons,
locomotor dysfunction, and early mortality. However, the
phenotype caused by the G2019S-LRRK2 mutant is more
severe than that cause by the expression of equivalent
levels of WT LRRK2. Treatment with L-DOPA improvesParkinson’s Disease 7
the mutant LRRK2-induced locomotor impairment but does
notpreventthelossofTH-positiveneurons.Someﬂymodels
that overexpress other LRRK2 mutations, such as I1122V,
Y1699C,andI2020T,showsimilarresults,intermsofanage-
dependent impairment of locomotor activity that improves
with DA stimulation, and the loss of DA neurons [113–115].
Moreover, in transgenic C. elegans,D Am a r k e rl o s si sg r e a t e r
in those expressing G2019S LRRK2 than WT LRRK2 [116].
Transgenic mice made using bacterial artiﬁcial chromo-
some (BAC) technology and expressing WT LRRK2, or the
R1441G or G2091S mutation exhibit mild axonal pathology
in the nigrostriatal DA projection [117, 118]. However,
the conditional overexpression of neither WT LRRK2 nor
its G2019S mutation causes degeneration of the DA-
containingneurons[119].Interestingly,althoughtheLRRK2
conditional transgenic mice show minimal nigrostriatal
pathologies, they exhibit a progressive age-dependent motor
impairment that is improved by DA stimulation. LRRK2
involvement in the pathogenesis of PD may be limited,
and other genetic and/or environmental factors are probably
required to trigger DA neuronal degeneration.
LRRK2 KO mice are viable, have no major abnormalities,
andlivetoadulthood,andthereisnosigniﬁcantdiﬀerencein
the susceptibility of LRRK2-deﬁcient and WT mice to MPTP
[120]. In LRRK2-KO Drosophila models, diﬀering results
on the pathology of the DA neurons have been obtained
[111, 121]. Lee et al. showed that LRRK loss-of-function
mutants exhibited severely impaired locomotive activity
[111]. Moreover, DAergic neurons in LRRK mutants showed
a severe reduction in tyrosine hydroxylase immunostaining
and shrunken morphology. Conversely, Wang et al. demon-
strated that mutants lacking dLRRK kinase activity are viable
with normal development and life span as well as unchanged
number and pattern of DAergic neurons [121]. Nematode
deletion mutants indicate that LRRK2 is dispensable for the
development and maintenance of DA neurons [122].
8.4. Parkin. Parkin covers approximately 1.3 Mb of genomic
DNA and is the causative gene for representative AR juvenile
PD (PARK2). Mutations in parkin are not only a cause of
familial PD but are also seen in 20% of young-onset sporadic
PDcases[123].ParkinisanE3ubiquitinligasethatfunctions
in the ubiquitin-proteasome system. The loss of parkin
function is believed to result in abnormal accumulations of
parkin’s substrates. Springer et al. demonstrated that pdr-
1 (the nematode parkin homolog) mutants are viable and
display no obvious morphological defects or alterations in
motility, egg-laying behavior, brood size, or life span under
standardgrowthconditions[124].Moreover,theauthorsdid
not detect any eﬀect of the mutations on the survival of
the DA neurons in the worms. However, overexpression of
the α-synuclein A53T mutation in pdr-1 mutants leads to
developmental arrest and lethality, indicating this C. elegans
model recapitulates parkin insolubility and aggregation
similar to several AR juvenile PD-linked parkin mutations
[124].
Drosophila parkin-null mutants exhibit a reduced lifes-
pan, locomotor defects (ﬂight and climbing abilities), and
male sterility [125, 126]. The locomotor defects derive from
the apoptotic cell death of muscle subsets whereas the male
sterile phenotype derives from a spermatid individualization
defect at a late stage of spermatogenesis. Mitochondrial
pathology is the earliest manifestation of muscle degen-
eration and a prominent characteristic of individualizing
spermatids in parkin mutants. These mutants also display
a decrement in the TH level and degeneration of a subset
of DA neurons in the brain [126]. Several parkin-null
mice have been generated and display motor and cognitive
deﬁcits including reduced locomotor activity and decreased
spontaneous alteration in the T-maze; however, they show
no substantial DAergic behavioral abnormalities [127–130].
Pathologically,KOmiceexhibitslightlyabnormalDAnigros-
triatal and locus coeruleus noradrenergic regions [128, 129].
The overexpression of human mutant parkin in Dro-
sophila causes an age-dependent, selective degeneration of
DA neurons accompanied by progressive motor impairment
[131, 132]. Parkin-Q311X mice also exhibit multiple late-
onset and progressive hypokinetic motor deﬁcits [133].
Stereological analyses revealed that the mutant mice develop
age-dependent DA neuron degeneration in the substantia
nigra and a signiﬁcant reduction of the striatal DA level,
accompanied by a signiﬁcant loss of DA neuron terminals
in the striatum. These results indicate that parkin mutants
may play a pivotal role in the dominant-negative etiological
mechanisms of PD.
8.5. PINK1. PINK1 is another causative gene for the AR
inherited PD called PARK6. PARK6 is the second most
frequent early-onset AR PD. PINK1 is located in mito-
chondria and is a putative mitochondrial kinase, because
it contains a conserved serine/threonine kinase domain
with an N-terminal mitochondrial-targeting motif [134].
Thus, the PD-causative mutations of PINK1 may cause loss
of function. Park et al. and Clark et al. generated and
characterized loss-of-function Drosophila PINK1 mutants
[135,136].Theseﬂiesexhibitmalesterility, apoptotic muscle
degeneration, defects in mitochondrial morphology, and
increased sensitivity to multiple stresses, including oxidative
stress.
Parketal.showedanage-dependentdecreaseinDAlevels
and a mild loss of DA neurons in these Drosophila mutants
[135].Notably,thePINK1mutantssharemarkedphenotypic
similarities with parkin mutants. Parkin overexpression is
able to rescue the mitochondrial defects found in PINK1,
although the double mutants do not show an enhanced phe-
notype. PINK1 overexpression does not rescue parkin phe-
notypes. Together, the data indicate that parkin and PINK1
function, at least partly, in a common pathway, and PINK1
acts upstream of parkin. Whereas PINK1-deﬁcient mice
show age-dependent mitochondrial dysfunction, increased
sensitivity to oxidative stress, decreased evoked DA release,
and DA receptor agonist-responsive impairment of striatal
plasticity, the number of DA neurons, the level of striatal DA,
and the level of DA receptors are the same as in WT animals
[137–139]. These phenotypes are similar to those of parkin-
KO mice.8 Parkinson’s Disease
8.6. DJ-1. Deletion or point mutations in DJ-1 have been
i d e n t i ﬁ e di ne a r l yo n s e tA RP D( PARK7). DJ-1 plays a
role as an antioxidant and chaperone, and it is expressed
ubiquitously in the cytosol, mitochondrial matrix, and
intermembranous space [140]. In vitro, downregulation or
KO of the endogenous DJ-1 increases cells’ vulnerability
to oxidative stress and proteasome inhibition, implicating
it in the cellular response to oxidative stress [141–143].
Drosophila possesses two diﬀerent orthologs of the human
DJ-1 gene, named DJ-1α and DJ-1β. While loss-of-function
DJ-1β mutants have normal numbers of DA neurons,
classical genetic analyses and RNAi experiments have yielded
contradictory results regarding the function of DJ-1α in DA
neuron maintenance [144–148]. However, DA neuron loss
cannotbedetectedinDJ-1α/DJ-1β double-deletionmutants,
which are also viable, fertile, and have a normal life span.
Some studies have reported a loss of DA neurons upon acute
RNA silencing of DJ-1α [147, 148].
Similar to α-synuclein and parkin KO mice, DJ-1 KO
mice do not show major DA-agonist-responsive behavioral
abnormalities or the loss of nigrostriatal DA neurons [149–
151]. In particular, although the levels of striatal DA and
DA receptors are unchanged, the evoked dopamine release
from striatal slices is clearly reduced, most likely as a
consequence of increased reuptake. DJ-1 mutant mice also
show an increased sensitivity to MPTP [150]. This is rescued
by restoring the DJ-1 expression in mutant mice, further
indicating a role for DJ-1 in the oxidative stress response.
8.7. HtrA2/Omi. HtrA2/Omi has been identiﬁed as the
causative gene for a rare inherited PD, PARK13.H t r A 2 / O m i
has a PDZ domain in addition to a serine protease
domainandislocalizedtothemitochondrialintermembrane
space by its mitochondria-targeting sequence. Whitworth
et al. have demonstrated a genetic interaction between
HtrA2/Omi and PINK1, described below, by investigating
the eye phenotype of double mutant ﬂies [152]. Their study
revealed that HtrA2/Omi acts downstream of PINK1 and is
independent of the parkin gene. Yet, Yun et al. indicated
thatHtrA2/Ominullﬂymutantsshowneithermitochondrial
morphologicaldefectsnorDAergicneuronalloss[153].They
also generated a Drosophila HtrA2/Omi mutant analogue
to the human mutation G399S, which was identiﬁed in
PARK13 patients. HtrA2/Omi G399S retains a signiﬁcant,
if not complete, function of HtrA2/Omi, compared with
protease-compromised versions of the protein, indicating
that HtrA2/Omi is unlikely to play a pivotal role in
PD pathogenesis or as an etiological factor. The targeted
deletion of HtrA2/Omi in mice increases their sensitivity
to stress-induced cell death [154, 155]. Animals lacking
HtrA2/Omi display a progressive movement disorder similar
to progressive akinesia, a rigidity syndrome, showing lack of
coordination, decreased mobility, bent posture, tremor, and
a decreased number of TH-positive striatal neurons [155].
8.8. Nurr1 (NR4A2). Nurr1 is a member of the nuclear
receptor superfamily and is involved in the diﬀerentiation
and development of nigrostriatal DA neurons. Le et al.
identiﬁed two mutations in Nurr1 associated with Parkinson
disease (–291Tdel and –245T→G), which map to the ﬁrst
exon of NR4A2 and aﬀected one allele in 10 of 107 indi-
viduals with familial Parkinson disease [156]. Mutations in
Nurr1 alter the transcription of TH and the DA transporter,
suggesting that alterations in Nurr1 may cause chronic
DA alterations that could increase susceptibility to PD
[157]. Nurr1 is essential for the development of the ventral
mesencephalic DA neurons, because homozygous Nurr1-KO
mice do not develop DA neurons in the substantia nigra
and die soon after birth [158]. Heterozygous Nurr1-KO mice
exhibit a signiﬁcant decrease in rotarod performance and
locomotor activities [159]. These phenotypes are associated
with decreased DA levels in the striatum, decreased numbers
of DAergic neurons, and a reduced expression of Nurr1 and
DAT in the substantia nigra. Moreover, Le et al. reported that
heterozygous Nurr1-KO mice show a signiﬁcant decrease
in the total number of TH-positive neurons in the sub-
stantia nigra and reduced DA in the striatum after MPTP
administration [160]. Thus, these mice show a progressive
DA phenotype that bears some resemblance to that found
in α-synuclein-overexpressing and mutant mice. Therefore,
Nurr1-knockdown mice may provide a good model for
investigating the later stages of PD characterized by severe
DA neuron loss.
9. Concluding Remarks
T h es y m p t o m so fP Db e c o m ea p p a r e n ta f t e rm o r et h a n8 0 %
oftheDAneuronshavedied.Therateofsubstantianigralcell
loss is assumed to be about 2,500 per year in normal people.
T h el o s so fD Af u n c t i o nc a nb ea c c e l e r a t e db ye x p o s u r e
to neurotoxins and by molecular (genetic) abnormalities,
leading to a fast and signiﬁcant decrease in the number of
DA neurons. Consequently, these pharmacological and/or
genetic insults can cause early onset of PD. This scenario
indicates that critical pathological changes could be initiated
one or two decades prior to the onset of PD.
Asdescribedabove,whetherthecausativefactorisatoxic
compound or a mutated gene, we have no perfect animal
models of PD. So far, the neurotoxin-induced vertebrate
modelsofPDaresuitableforinvestigatingdisease-modifying
therapies, since they have already proved predictive. Several
genetic animal models of PD are useful for understanding
the early processes of degeneration in the nigrostriatal DA
system. In particular, transgenic α-synuclein animals are
valuable for researching general toxicity eﬀects and the
mechanismsofα-synucleinpathology,aswellasforconﬁrm-
ingpotentialtherapeuticstrategies.Recently,causativemuta-
tions and risk factors for PD have been identiﬁed in more
g e n e s .T h eh o m o z y g o u sl o s so ff u n c t i o no fglucocerebrosidase
(GBA) causes Gaucher’s disease whereas its heterozygous
loss of function increases the risk of developing sporadic
PD [161]. ATP13A2 is causative for a juvenile onset AR
hereditaryPDwithdementia(PARK9)[162].Animalmodels
of these mutations have not been described, but once they
are available, they will undoubtedly shed new light on the
mechanisms of PD.Parkinson’s Disease 9
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